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Case Report 
Introduction 
Oral systemic glucocorticoids (GC) are widely used in 
medical practicesin transplantology and for treating 
asthma, systemic connective tissue disorders, and 
various autoimmune diseases. The therapy is usually 
continued for more than three months. However, on 
chronic use, GCs are considered one of the contributing 
causes of secondary and iatrogenic osteoporosis. Studies 
in various centres have shown that usage of 5mg        
predinisone per day causes increased bone loss in the 
initial 6 to 12 months with low daily dosing of 2.5 mg 
of prednisolone, in intermittent and repeated cycles, also 
having a cumulative and deleterious effect.[1] The risk 
is usually higher in the initial three months of 
continuous therapy and slowly decreases after its 
discontinuation; however, it does not resume normalcy.
[2] 
The GC-induced bone disease mainly affects trabecular 
bone, justifying the higher occurrence of vertebral and 
rib fractures. The potentiality of GC causing fractures is 
often neglected by professionals and ignored by the 
patient and their caregivers. Relative risk increases with 
dose and duration of therapy, while the absolute risk can 
be determined by a range of associated clinical 
conditions. The present report describes a case of GC 
induced fracture in an elderly female patient of 
rheumatoid   arthritis. 
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Case Description 
A 65 years old normotensive euglycemic female 
presented with a fracture in mid shaft of tibia following 
a very low-velocity trauma. On history elicitation, she 
was found to have been treated for rheumatoid arthritis 
with methylprednisolone 4mg once daily, sulfasalazine 
500 mg twice daily and vitamin D3 calcium 
supplementation for last one year. The patient had a 
sedentary  lifestyle and a positive familial history of 
osteoporotic fracture. She was advised to continue all 
medicines with the addition of alendronic acid 70 mg 
once weekly with plaster cast being done. 
After four weeks, the patient presented with a burning 
sensation in the throat, along with severe hyperacidity. 
Alendronate was withdrawn. Pantoprazole and 
domperidone combination was prescribed. Laboratory 
investigations suggested FPG 98 mg/dl, serum 
creatinine - 0.8 mg/dl, hemoglobin - 11.7 gm/dl, serum 
calcium - 9.80 mg/dl, alkaline phosphatase- 100 U/L, 
TSH - 3.1 uIU/ml, Vit 25 OH D - 40 ng/ml, normal liver 
profile. Dual-energy X-ray absorptiometry (DEXA) 
scan revealed     T-score of – 3.1 at the femoral neck 
and T-score of - 2.9 at spine. FRAX score was 23.The 
patient was advised injection teriparatide 20 mcg SC 
once daily, methotrexate 15 mg once weekly, folic acid 
5 mg four days in a week, hydroxychloroquine 200 mg 
twice daily, sulfasalazine 1000 mg twice daily, calcium 
and vitamin D   supplementation. On review after two 
months, patients presented with no more complaints, 
methotrexate dose was down titrated to 7.5 mg once 
weekly with other medications continuing. 
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Abstract 
Oral systemic glucocorticoids widely used in the medical practice to treat various diseases like asthma, systemic 
connective tissue diseases, other autoimmune diseases and in transplantology, are considered the main cause of 
secondary and iatrogenic osteoporosis. The pathogenesis of glucocorticoid-induced bone loss is multifactorial and 
complex. The exact mechanism remains undefined. The present report describes a case of 65 years old female 
presenting with fracture in mid shaft of tibia after a very low velocity trauma. On medical history elicitation, she was 
found to be treated for rheumatoid arthritis with oral glucocorticoids. Causality, severity and preventability 
assessment was done for the reaction. Potentiality of glucocorticoids causing fractures is often neglected by 
professionals and ignored by patient and their caregivers. Given the potential for rapid bone loss with glucocorticoid 
therapy, frequent monitoring is warranted while bearing in mind that BMD is a surrogate marker for fracture risk and 
patients on glucocorticoids fracture at higher BMD than other patients. Once treatment is initiated, BMD should be 
monitored annually to ensure compliance and efficacy.  
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Causality assessment of this adverse event was found to 
be ‘Possible’ under WHO UMC Causality Assessment 
Scale.[3] A score of 3 could be attributed under 
Naranjo’s algorithm[4], which confers it to be 
‘Possible’. The event was ‘preventable’ under 
Schumock and Thornton’s preventability assessment 
criteria [5]. Severity assessment using Hartwig Seigel’s 
Scale [6] conferred it to be moderate (Level 3). The 
event was reported under the National 
Pharmacovigilance Programme. 
Discussion 
Bone and muscle form a unit, with mutual trophic 
influence. Chronic GC use causes decreased bone            
remodelling and low bone turnover. Trabecular bone 
loss, including vertebrae and the femoral neck, are 
usually the most significantly affected ones.[7]Fracture 
risk at a specific bone mineral density (BMD) is greater 
for patients on GC therapy than the same BMD in a non
-GC-treated patient, making it imperative that clinicians 
use different BMD thresholds for initiating osteoporosis 
treatments in these patients. Studies have shown a 
strong association between oral GC dose and fracture 
risk with greatest risk being during the initial 3-6 
months of treatment initiation with GC.  
Pathogenesis of GC induced bone loss is intricate. GCs 
increase the expression of parathyroid hormone (PTH) 
receptors in osteoblasts and enhance osteoblasts       
response to PTH. GC inhibits intestinal calcium       
absorption by vitamin D independent factors.            
Expression of the gene encoding calbindin-D28K, a 
protein involved in intestinal calcium transport is also 
implicated. In patients receiving GCs, serum levels of 
vit. D metabolites are usually in the normal range, 
serum levels of PTH are variable and generally has been    
reported to be normal. GCs produces a dose-related   
inhibition of osteoblasts maturation precursors, with a 
decreased number of osteoblasts in the matrix and the 
synthesis of both type I collagen and non-collagenous 
proteins by osteoblasts. GC inhibits gonadotropins, sex 
steroids and adrenal androgen production and release, 
which accelerates bone loss. Inhibition of prostaglandin 
E2, transforming growth factor β1 and transcription and 
synthesis of Insulin-like growth factors are also 
implicated, which are a direct or indirect determinant of 
bone health. 
GCs also have indirect effects on local growth factors 
such as fibroblast growth factors, platelet-derived 
growth factors, bone morphogenetic proteins, cytokines 
like IL 6, 11, colony stimulating factors. With direct 
action on the collagen and collagenases, GC causes the 
decreased bone formation and increased resorption. In 
the initial phase of therapy, there is increased 
osteoclastic activity coupled with increased bone 
resorption  leading to rapid loss of bone integrity and 
significant fracture risk. Later in the course of treatment, 
resorption slows, resulting in a state of chronically 
decreased bone turnover. Osteoblast signaling is also 
affected, causing reduced osteoprotegerin release and 
increased receptor activator of NF-KB ligand, resulting 
in osteoclastogenesis. Other actions of GC that 
negatively affect bone include decreased calcium 
absorption by the gastrointestinal tract and renal 
calcium loss. Fracture risk is also associated with 
steroid myopathy resulting in muscle weakness. [8, 9] 
The GC-induced bone loss remains an important 
consequence of GC therapy, which is partially 
reversible, and hence, prevention should be considered 
and discussed in all patients during initiation of GC 
treatment. Patients receiving GC on a long-term basis 
should have a calcium intake of 1,500 mg/d, and their 
hypercalciuria should be controlled by sodium 
restriction, and if     necessary, a thiazide combined with 
a potassium-sparing diuretic. Gonadal hormones should 
be replaced when deficient, and adequate levels of 25 
OH-vitamin D should be assured. Physical activity 
should be encouraged. Preliminary studies suggest that 
bisphosphonates may be useful in the prevention of 
bone loss. Calcitonin and sodium fluoride may be useful 
in       patients with significant GC-induced osteoporosis 
(GIO). It is time to be aggressive in preventing and 
treating GC-induced bone loss in all patients regardless 
of symptoms. For premenopausal women and men   
under the age of 50 years, fracture risk should be      
determined, and treatment decisions based on this    
assessment. In postmenopausal women and older men, 
the risk of GIO and fractures is greater and the evidence 
demonstrating the benefit of preventative  therapy is 
clear. In our opinion, these patients should be initiated 
on preventative therapy. Currently, guidelines 
recommend oral bisphosphonate therapy as first-line 
treatment, with  adjuvant calcium and vitamin D. New 
evidence suggests greater BMD gains with zoledronic 
acid and PTH and these therapies may, therefore, 
provide important options particularly in high-risk 
patients with established GIO. [10] 
Conclusion 
Given the potential for rapid bone loss with GC therapy, 
frequent monitoring is warranted while bearing in mind 
that BMD is a surrogate marker for fracture risk and 
patients on GC fracture at higher BMD than other    
patients. Once treatment is initiated, BMD should be 
monitored annually to ensure compliance and efficacy. 
Further research is needed to define in an evidence-
based manner the most efficient frequency of BMD 
monitoring and the optimal duration of treatment with 
bisphosphonates. 
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